Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric Study
The present study suggests that dose reduction may not compromise the efficacy of osimertinib. However, the clinical impact of dose reduction is not fully understood. Physicians should carefully weigh its benefits and risks before implementation.
Authors
- Kosuke Narita (ORCID: https://orcid.org/0000-0003-2498-3438)
- Yukari Shirakura
- Hirokazu Iso (ORCID: https://orcid.org/0000-0002-3672-679X)
- Makiko Yomota (ORCID: https://orcid.org/0000-0002-1616-9893)
- Masahiro Seike (ORCID: https://orcid.org/0000-0002-1572-5472)
- Yukio Hosomi (ORCID: https://orcid.org/0000-0002-3849-5905)
- T Yoshinaga (ORCID: https://orcid.org/0009-0007-4059-149X)
- Shoko Kawai (ORCID: https://orcid.org/0000-0003-3642-7391)
Institutions
- Tokyo Metropolitan Komagome Hospital (JP)
- Nippon Medical School (JP)
Publication Details
- Journal
- OncoTargets and Therapy
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/ott.s494112
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52